PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50122C00082 — THIS ACQUISITION WILL ALLOW BARDA TO INVEST PROJECT BIOSHIELD FUNDS FOR LATE-STAGE CLINICAL DEVELOPMENT, REGULATORY APP…

THIS ACQUISITION WILL ALLOW BARDA TO INVEST PROJECT BIOSHIELD FUNDS FOR LATE-STAGE CLINICAL DEVELOPMENT, REGULATORY APP… is a federal NONE award for Department of Health and Human Services (HHS) held by AKTIVAX INC. Estimated value $45.3M ($45.3M obligated). Current period of performance ends Dec 31, 2026 (potential Dec 31, 2039). Last award drew 2 bidders.

$45.3M
Estimated Value
Dec 31, 2026
PoP End / Expires
2
Bidders (last award)
AKTIVAX INC
Incumbent

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

AKTIVAX INC holds — across 1 federal awards. Competition previously drew 2 offers. Set-aside status: NONE. Recompete timing centers on the Dec 31, 2026 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract number75A50122C00082
AgencyDepartment of Health and Human Services (HHS)
IncumbentAKTIVAX INC
UEIT1XHPCDJ4NT6
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN12
PoP end (current)Dec 31, 2026
PoP end (w/ options)Dec 31, 2039
Obligated$45.3M

THIS ACQUISITION WILL ALLOW BARDA TO INVEST PROJECT BIOSHIELD FUNDS FOR LATE-STAGE CLINICAL DEVELOPMENT, REGULATORY APPROVAL FOR 2-PAM AUTOINJECTORS (AS A DRUG/DEVICE COMBINATION PRODUCT) TO TREAT ORGANOPHOSPHATE (OP) POISONING, INCLUDING NERVE AGENT

Recompete timing

Public
Expiring in 137 days

Current PoP ends Dec 31, 2026 (137 days remaining). Agencies typically plan 12–18 months ahead — at 4.5 months out, that window is already open. The buying decision is likely already in motion.

Watch this contract — one email →

Incumbent footprint

Public record

AKTIVAX INC obligated across 1 awards (firm-wide, all agencies).

Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open AKTIVAX INC’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75A50122C00082?

75A50122C00082 (THIS ACQUISITION WILL ALLOW BARDA TO INVEST PROJECT BIOSHIELD FUNDS FOR LATE-STAGE CLINICAL DEVELOPMENT, REGULATORY APP…) is a Department of Health and Human Services (HHS) award with an estimated value of $45.3M, currently held by AKTIVAX INC. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75A50122C00082?

AKTIVAX INC is the incumbent with — across 1 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2026.

When does 75A50122C00082 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50122C00082